Twist Bioscience financials
$186.13+3.64%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 Jun 30 | Q2 '26 Mar 31 | Q1 '26 Dec 31 | Q4 '25 Sep 30 | Q3 '25 Jun 30 | Q2 '25 Mar 31 | Q1 '25 Dec 31 | Q4 '24 Sep 30 | Q3 '24 Jun 30 | Q2 '24 Mar 31 | Q1 '24 Dec 31 | Q4 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $118.4M | $110.7M | $103.7M | $99.0M | $96.1M | $92.8M | $88.7M | $84.7M | $81.5M | $75.3M | $71.5M | $66.9M |
| Gross profit | $62.5M | $57.1M | $54.0M | $50.8M | $51.3M | $46.0M | $42.8M | $38.2M | $35.3M | $30.9M | $29.0M | $24.5M |
| Gross margin | 52.8% | 51.6% | 52.0% | 51.3% | 53.4% | 49.6% | 48.3% | 45.1% | 43.3% | 41.0% | 40.5% | 36.6% |
| Operating income | -$36.3M | -$45.9M | -$32.9M | -$29.9M | -$30.1M | -$41.6M | -$34.6M | -$36.0M | -$88.9M | -$48.9M | -$47.0M | -$50.1M |
| Net income | -$35.1M | -$44.0M | -$30.5M | -$27.1M | $20.4M | -$39.3M | -$31.6M | -$34.7M | -$85.6M | -$45.5M | -$43.0M | -$46.2M |
| Net margin | −29.6% | −39.8% | −29.4% | −27.4% | 21.2% | −42.4% | −35.6% | −40.9% | −105.0% | −60.4% | −60.2% | −69.1% |
| Diluted EPS | $-0.56 | $-0.71 | $-0.50 | $-0.46 | $0.33 | $-0.66 | $-0.53 | $-0.59 | $-1.47 | $-0.79 | $-0.75 | $-0.81 |
| EBITDA | -$29.5M | -$32.2M | -$26.7M | -$23.9M | -$24.1M | -$35.2M | -$28.3M | -$74.3M | $9.2M | -$40.6M | -$38.8M | -$32.2M |
| Operating cash flow | $1.1M | -$17.6M | -$24.8M | -$11.8M | -$1.4M | -$13.0M | -$21.4M | -$15.3M | -$6.4M | -$19.4M | -$23.0M | -$20.7M |
| Free cash flow | -$8.6M | -$30.4M | -$34.8M | -$24.2M | -$10.6M | -$17.1M | -$23.7M | -$17.3M | -$7.3M | -$20.0M | -$24.5M | -$23.1M |
| Diluted shares | 62.4M | 61.7M | 61.1M | 59.3M | 61.2M | 59.6M | 59.2M | 58.6M | 58.1M | 57.8M | 57.5M | 57.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $117.4M | $122.7M | $148.6M | $183.0M | $201.4M | $210.4M |
| Short-term investments | $49.4M | $49.0M | $49.4M | $49.4M | $49.4M | $46.7M |
| Total debt | $15.0M | $15.0M | $15.0M | $15.0M | $15.0M | $15.0M |
| Total assets | $672.4M | $676.2M | $638.1M | $641.9M | $643.6M | $595.6M |
| Total liabilities | $226.7M | $221.1M | $182.0M | $168.9M | $165.4M | $155.5M |
| Shareholders' equity | $445.7M | $455.1M | $456.1M | $473.0M | $478.2M | $440.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology